Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04646187Phase 4Enrolling By Invitation

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

Role: collaborator

NCT04548778Completed

BÜHLMANN FPELA in the Diagnosis of Exocrine Pancreatic Insufficiency

Role: lead

NCT02351635Completed

BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS

Role: lead

NCT03408249Not ApplicableCompleted

IBDoc® Canadian User Performance Evaluation

Role: lead

All 4 trials loaded